Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SYNERGY-NASH

SYNERGY-NASH

Tirzepatide · MASH F2–F3

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
MASH F2–F3
Official title
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Sponsor
Eli Lilly and Company
Phase
Phase 2
Registry status
completed · 2019-11 → 2023-12
Participants
190
Duration
52 weeks
Registry
NCT04166773

Outcomes in the indication

SYNERGY-NASH Tirzepatide · MASH F2–F3 · 52 weeks · n = 190 seed

MASH resolution without worsening fibrosis 44–62 % vs 10 %

MeasureDrugControlDifference (95 % CI)Status
MASH resolution without worsening of fibrosis - tirzepatide 10 mg 10 mg
week 52
+56.0+10.0+46.0 (+29.0 to +62.0) percentage pointsverified
MASH resolution without worsening of fibrosis - tirzepatide 15 mg 15 mg
week 52
+62.0+10.0+53.0 (+37.0 to +69.0) percentage pointsverified
MASH resolution without worsening of fibrosis - tirzepatide 5 mg 5 mg
week 52
+44.0+10.0+34.0 (+17.0 to +50.0) percentage pointsverified
Verbatim quotes (3)
  • MASH resolution without worsening of fibrosis - tirzepatide 10 mg
    56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62)
  • MASH resolution without worsening of fibrosis - tirzepatide 15 mg
    62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69)
  • MASH resolution without worsening of fibrosis - tirzepatide 5 mg
    44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SYNERGY-NASH. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synergy-nash/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.